argenx SE (ARGX) Presents at Morgan Stanley twenty third Annual International Healthcare Convention

Sean Laaman
Head of Healthcare Analysis & Fairness Analyst

Good morning. Welcome to Morgan Stanley’s International Healthcare Convention. I am Sean Laaman, Head of SMID-cap Biotech Fairness Analysis right here on the agency. Earlier than we proceed additional, for necessary disclosures, please see the Morgan Stanley analysis disclosure web site at www.morganstanley.com/researchdisclosures. And when you’ve got any questions, please attain out to your Morgan Stanley gross sales consultant.

For this session, we’ve from argenx, a pleasure to host the CFO, Karl Gubitz. So welcome, and thanks on your time in the present day, Karl. And possibly simply to kick off proceedings, I will get a couple of minutes from you simply to set the scene. We’ll have some macro-type questions, after which we’ll go into the center of it. So welcome, Karl. Thanks.

Karl Gubitz
Chief Monetary Officer

Thanks. Thanks, Sean. Good morning, everyone. Vivid and early. It is an actual pleasure to be right here. At argenx, we’re on an innovation mission. We all know that’s the solely motive we exist. Sufferers are ready. In doing this, we set ourselves very formidable targets firstly of the yr and once we exit and execute on these. Biotechs many occasions falter at execution. At argenx, it’s certainly one of our core strengths. For this yr, our targets had been, firstly, industrial execution. I believe our Q2 revenues, product web gross sales of $949 million answered that query. We’re doing rather well.

On the scientific aspect, within the first half of the yr, we had 2 targets. CIDP CHMP approval, we have finished that. And the second, which was actually necessary was the PFS launch in